MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

2 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

2 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

1 months ago

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

1 day ago

Is Aldeyra Therapeutics on the Brink of a Breakthrough with Reproxalap

1 months ago

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics is advancing zorevunersen for Dravet syndrome, with phase 3 EMPEROR trial data expected by mid-2027. The company plans a rolling NDA submission in 1H 2027, supported by three-year o...

STOK

Stock News•5 days ago

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript

Ionis Pharmaceuticals (IONS) released its Q1 2026 earnings transcript, providing updates on its financial performance and pipeline progress. The report details the company's current operational status...

IONS

Stock News•1 week ago

This Drug Stock Nears A Buy Point, With Profit Set To Explode

A biopharma stock is currently testing a key moving average within a technical base. The company utilizes proprietary, patented technology for its drug administration, which may influence future marke...

LQDA

Stock News•1 week ago

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Biogen enters Q1 earnings with growth driven by new product launches, including Skyclarys and Zurzuvae. Investors are monitoring whether these gains can successfully offset the ongoing revenue decline...

BIIB